A trial of lixisenatide to assess its effects in early Parkinson’s disease.
Phase 2 trial reveals Lixisenatide may reduce motor disability in Parkinson’s patients
- Post author:
- Post published:April 18, 2024
- Post category:uncategorized
Empowering individuals with knowledge, fostering healthier lifestyles, and fostering a community dedicated to diabetes awareness and prevention. Together, we’re shaping a healthier future.
Subscribe To Us
By submitting via this part of the website you are granting us permission to store and process your data according to our Standard privacy policy
© 2026 Diabetes Prevention Awareness Center.